{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qin L"],"funding":["NICHD NIH HHS"],"pagination":["657-670"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8404148"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(10)"],"pubmed_abstract":["Steroid receptor coactivators (SRCs) possess specific and distinct oncogenic roles in the initiation of cancer and in its progression to a more aggressive disease. These coactivators interact with nuclear receptors and other transcription factors to boost transcription of multiple genes, which potentiate cancer cell proliferation, migration, invasion, tumor angiogenesis and epithelial-mesenchymal transition (EMT). Targeting SRCs using small molecule inhibitors (SMIs) is a promising approach to control cancer progression and metastasis. By high-throughput screening analysis, we recently identified SI-2 as a potent SRC SMI. To develop therapeutic agents, SI-10 and SI-12, the SI-2 analogs are synthesized that incorporate the addition of F atoms to the SI-2 chemical structure. As a result, the"],"journal":["Endocrine-related cancer"],"pubmed_title":["Development of improved SRC-3 inhibitors as breast cancer therapeutic agents."],"pmcid":["PMC8404148"],"funding_grant_id":["R01 HD007857","R01 HD008188"],"pubmed_authors":["Peng X","Jain P","Qin L","Chen J","O'Malley BW","Lu D","Lonard DM","Wang J","Cardenas D","Yu X","Xu J","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Development of improved SRC-3 inhibitors as breast cancer therapeutic agents.","description":"Steroid receptor coactivators (SRCs) possess specific and distinct oncogenic roles in the initiation of cancer and in its progression to a more aggressive disease. These coactivators interact with nuclear receptors and other transcription factors to boost transcription of multiple genes, which potentiate cancer cell proliferation, migration, invasion, tumor angiogenesis and epithelial-mesenchymal transition (EMT). Targeting SRCs using small molecule inhibitors (SMIs) is a promising approach to control cancer progression and metastasis. By high-throughput screening analysis, we recently identified SI-2 as a potent SRC SMI. To develop therapeutic agents, SI-10 and SI-12, the SI-2 analogs are synthesized that incorporate the addition of F atoms to the SI-2 chemical structure. As a result, the","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-04T09:37:07.631Z","creation":"2025-04-04T09:37:07.631Z"},"accession":"S-EPMC8404148","cross_references":{"pubmed":["34310341"],"doi":["10.1530/erc-20-0402","10.1530/ERC-20-0402"]}}